Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 182-187

  Leff, Matthew A ^b,c   Epstein, Paul N ^c   Doll, Mark A ^b   Fretland, Adrian J ^b   Devanaboyina, Udaya Sankar ^a,b   Rustan, Timothy D ^c   Hein, David W ^b,c  

^a Toxicol and Pathol Services Inc   (United States)

^b University of Louisville School of Medicine   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; HETEROCYCLIC AMINE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; AUTORADIOGRAPHY; BIOTRANSFORMATION; CARCINOGENS; CYTOSOL; DNA ADDUCTS; FLUORENES; HUMANS; IMIDAZOLES; MALE; MICE; MICE, TRANSGENIC; PROSTATE; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0032967592     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Agundez JAG, Martinez C, Olivera M, Gallarado L, Ladero JM, Rosado C, Prados J, Rodriguez-Molina J, Resel L and Benitez J (1998). Expression in human prostate of drug-and carcinogen-metabolizing enzymes: Association with prostate cancer risk. Br J Cancer 78:1361-1367.
2. Barrios R, Lebovitz RM, Wiseman AL, Weisoly DL, Matusik RJ, DeMayo F and Lieberman MW (1996) Ras T24 driven by a probasin promoter induces prostatic hyperplasia in transgenic mice. Transgenics 2:23-28.
3. Buonarati MH, Turteltaub KW, Shen NH and Felton JS (1990) Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine to intermediates which bind DNA. Mutat Res 245:185-190.
4. PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
5. Cameron ER (1997) Recent advances in transgenic technology. Mol Biotech 7:253-265.
6. Chou H-C, Lang NP and Kadlubar FF (1995) Metabolic activation of N-hydroxy arylamines and W-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res 55:525-529.
7. Crofts FG, Sutter TR and Strickland PT (19981 Metabolism of 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine by human cytochrome P4501A1, P4501A2, and P4501B1. Carcinogenesis 19:1969-1973.
8. Doll MA, Fretland AJ, Deitz AC and Hein DW (1995) Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 231:413-420.
9. Doll MA, Jiang W, Deitz AC, Rustan TD and Hein DW (1997) Identification of a novel allele at the human NAT2 acetyltransferase locus. Biochem Biophys Res Commun 233:584-591.
10. Feng Y, Jiang W and Hein DW (1996) 2-Aminofluorene-DNA adduct levels in tumor-target and non-target organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol Appl Pharmacol 141:248-255.
11. Fretland AJ, Doll MA, Gray K, Feng Y and Hein DW (1997) Cloning, expression, and recombinant expression of NAT1, NAT2, and NAT3 derived from C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: Functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol Appl Pharmacol 142:360-366.
12. Glowinski IB and Weber WW (1982) Genetic regulation of aromatic amine N-acetylation in inbred mice. J Biol Chem 257:1424-1430.
13. Grant DM, Blum M, Beer M and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
14. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL and Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376:61-70.
15. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM and Matusik RJ (1994) The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 8:230-239.
16. Greenberg NM, DeMayo FJ, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439-3443.
17. 32P-poatlabeling analysis of aromatic carcinogen-DNA adducts. Cancer Res 45:5656-5662.
18. Hein DW, Doll MA, Fretland AJ, Gray K, Deitz AC, Feng Y, Jiang W, Rustan TD, Satran S and Wilkie TR (1997) Rodent models of the human acetylation polymorphism: Comparisons of recombinant acetyltransferases. Mut Res 376:101-106.
19. Hein DW, Doll MA, Fretland AJ and Leff MA (1998) Metabolic activation of N-hydroxy-2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (N-OH-PhIP) by twenty-three recombinant human NAT2 allozymes (Abstract). Proc Am Assoc Cancer Res 39:455.
20. Hein DW, Doll MA, Rustan TD and Ferguson RJ (1995) Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 55: 3531-3536.
21. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ and Grant DM (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638.
22. Hein DW, Rustan TD, Bucher KD, Furman EJ and Martin WJ (1991) Extrahepatic expression of the N-acetylation polymorphism towards arylamine carcinogens in tumor target organs of an inbred rat model. J Pharmacol Exp Ther 268:232-236.
23. Hein DW, Rustan TD, Ferguson RJ, Doll MA and Gray K (1994) Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltranaferases. Arch Toxicol 68:129-133.
24. Hein DW, Rustan TD, Martin WJ, Bucher KD, Miller LS and Furman EJ (1992) Acetylator genotype-dependent N-acetylation of arylamines in vivo and in vitro by hepatic and extrahepatic organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus. Arch Toxicol 66:112-117.
25. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shiu RPC, Snoek R and Matusik RJ (1994) Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269:31763-31769.
26. Lang NP, Butler MA, Massengill J, Lawson J, Stotta RC, Hauer-Jensen M and Kadlubar FF (1994) Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 3:675-682.
27. Levy GN and Weber WW (1989) 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. Carcinogenesis 10:705-709.
28. Lin D-X, Kaderlik KR, Turesky RJ, Miller DW, Lay JO, Jr. and Kadlubar FF (1992) Identification of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-6]pyridine as the major adduct formed by the food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-6]pyridine, with DNA. Chem Res Toxicol 5:691-697.
29. Lin D-X, Lang NP and Kadlubar FF (1995) Specific differences in the biotransformation of the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine by hepatic microsomes and cytosols from humans, rats, and mice. Drug Metab Dispos 23:518-524
30. Martell KJ, Levy GN and Weber WW (1992) Cloned mouse N-acetyltransferases: Enzymatic properties of expressed Nat-1 and Nat-2 gene products. Mol Pharmacol 42:265-272.
31. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF and Kadlubar FF (1992) N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorpnic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 185:839-844.
32. 32Postlabelling analysis of urinary mutagens from smokers of black tobacco implicates 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) as a major DNA-damaging agent. Carcinogenesis 12:713-717.
33. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA and Matusik RJ (1993) Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7:23-36.
34. Sanger F, Nicklen S and Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467.
35. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, Hasegawa R, Imaida K, Matsumoto K, Wakabayashi K, Sugimura T and Ito N (1997) The prostate: A target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res 57:195-198.
36. Trinidad A, Hein DW, Rustan TD, Ferguson RJ, Miller LS, Bucher KD, Kirlin WG, Ogolla F and Andrews AF (1990) Purification of hepatic polymorphic arylamine N-acetyltransferase from homozygous rapid acetylator inbred hamster: Identity with polymorphic N-hydroxyarylamine O-acetyltransferase. Cancer Res 50:7942-7949.
37. Turesky RJ, Constable A, Richoz J, Varga N, Markovic J, Martin MV and Guengerich FP (1998) Activation of heterocylic aromatic amines by rat and human rat and human liver microsomes and by purified rat and human cytochrome P4501A2. Chem Res Toxicol 11:925-936.
38. Turesky RJ, Lang NP, Butler MA, Teitel CH and Kadlubar FF (1991) Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis 12:1839-1845.
39. Valera A, Solanes G, Fernandez-Alvarez J, Pujol A, Ferrer J, Asins G, Gomis R and Bosch F (1994) Expression of GLUT-2 antisense RNA in beta cells of transgenic mice leads to diabetes. J Biol Chem 269:28543-28546.
40. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price-Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T and Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17.